News headlines about Xencor (NASDAQ:XNCR) have trended positive on Friday, Accern Sentiment Analysis reports. Accern ranks the sentiment of press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Xencor earned a news impact score of 0.38 on Accern’s scale. Accern also assigned news articles about the biopharmaceutical company an impact score of 33 out of 100, meaning that recent press coverage is unlikely to have an effect on the company’s share price in the near term.
These are some of the news articles that may have impacted Accern’s scoring:
- Xencor, Inc. (XNCR) Major Shareholder Purchases $29,505.00 in Stock (americanbankingnews.com)
- FDA Nod For Ipsen, XNCR On Watch, Results MAGNIFY CELG’s R2 Regimen (rttnews.com)
- FDA Nod For Ipsen, XNCR On Watch, Results MAGINIFY CELG’s R2 Regimen (nasdaq.com)
- Xencor (XNCR) Reports Interim Data from an Ongoing Open-Label Phase 2 Study of XmAb5871 in IgG4-Related Disease (streetinsider.com)
- Xencor Presents Interim Data from an Ongoing, Open-label, Phase 2 Study of XmAb®5871 in IgG4-Related Disease at EULAR 2017 (finance.yahoo.com)
Several analysts recently weighed in on the company. Wedbush restated an “outperform” rating and issued a $29.00 price objective on shares of Xencor in a report on Friday, June 16th. Zacks Investment Research upgraded Xencor from a “hold” rating to a “buy” rating and set a $29.00 price objective for the company in a report on Saturday, March 4th. Instinet assumed coverage on Xencor in a report on Wednesday, March 1st. They issued a “neutral” rating and a $21.00 price objective for the company. Finally, Nomura assumed coverage on Xencor in a report on Wednesday, March 1st. They issued a “neutral” rating for the company. Four equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Xencor currently has an average rating of “Buy” and a consensus target price of $28.67.
Shares of Xencor (NASDAQ:XNCR) traded down 1.104% during trading on Friday, reaching $21.955. 136,976 shares of the company’s stock were exchanged. The stock has a 50-day moving average price of $21.90 and a 200 day moving average price of $23.80. The company has a market capitalization of $1.03 billion, a P/E ratio of 62.195 and a beta of 2.13. Xencor has a 12-month low of $12.51 and a 12-month high of $29.38.
Xencor (NASDAQ:XNCR) last issued its earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.25) by $0.06. Xencor had a return on equity of 5.98% and a net margin of 18.19%. The business had revenue of $4.34 million for the quarter, compared to analyst estimates of $8.15 million. Equities analysts expect that Xencor will post ($1.21) EPS for the current fiscal year.
In other Xencor news, major shareholder John S. Stafford III bought 1,500 shares of the business’s stock in a transaction dated Friday, June 16th. The shares were acquired at an average price of $19.67 per share, with a total value of $29,505.00. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Edgardo Baracchini, Jr. sold 10,568 shares of the firm’s stock in a transaction dated Tuesday, May 2nd. The stock was sold at an average price of $26.01, for a total value of $274,873.68. Following the sale, the insider now directly owns 9,818 shares in the company, valued at approximately $255,366.18. The disclosure for this sale can be found here. Insiders have sold a total of 46,238 shares of company stock worth $1,037,822 in the last three months. Corporate insiders own 4.03% of the company’s stock.
Xencor Company Profile
Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.
Receive News & Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related companies with MarketBeat.com's FREE daily email newsletter.